YSOPIA Bioscience Announces the First Positive Safety Results of its CAUSALITY Study in Obesity and Associated Metabolic Disorders,  as well as the Inclusion of the Obese Patients in the Second Arm of the Trial
4 March 2021

YSOPIA Bioscience Announces the First Positive Safety Results of its CAUSALITY Study in Obesity and Associated Metabolic Disorders, as well as the Inclusion of the Obese Patients in the Second Arm of the Trial

YSOPIA Bioscience, a French clinical stage biotechnology company specializing in the research and development of innovative drugs using the properties of key bacterial strains...

Read the press release

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse